Tumor suppressor gene therapy for cancer: from the bench to the clinic

Drug Resistance Updates

Volumn 1, Issue 3, 1998, Pages 205-210

  Meng, Raymond D ^a   El Deiry, Wafik S ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0008407493     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-7646(98)80041-1     Document Type: Review

References (72)

1. Verma I.M., and Somia N. Gene therapy - promises, problems and prospects. Nature 389 (1997) 239-242
2. Paillard F. Cancer gene therapy annual conference 1997: Trends and news. Hum Gene Ther 9 (1998) 283-286
3. Emtage P.C.R., Wan Y.H., Bramson J.L., et al. A double recombinant adenovirus expressing the costimulatory molecule B7-I (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model. J Immunol 160 (1998) 2531-2538
4. Kanai F., Hamada H., Shiratori Y., and Omata M. Adenovirus-mediated enzyme-prodrug therapy for cancer. Cancer J 10 (1997) 301-305
5. Hesdorffer C., Ayello J., Ward M., et al. Phase I trial of retroviral-mediated transfer of the human MDRI gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 16 (1998) 165-172
6. Part 2 Suppl. Waller C.F., Maran A., Paranjape J.M., et al. Specific degradation of BCR/ABL mRNA and growth suppression of CML cells by 2-5A antisense oligonucleotides. Blood 90 (1997) 4020
7. Wang D., and Lin Q.S. Cationic liposome-mediated gene transfer. Prog Biochem Biophys 24 (1997) 486-491
8. Robbins P.D., Tahara H., and Ghivizzani S.C. Viral vectors for gene therapy. Trends Biotechnol 16 (1998) 35-40
9. He T.-C., Zhou S., da Costa L.T., et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95 (1998) 2509-2514
10. Ilan Y., Droguett G., Chowdhury N.R., et al. Insertion of the adenovirus E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long term gene expression. Proc Natl Acad Sci USA 94 (1997) 2587-2592
11. Scaria A., St. George J.A., Gregory R.J., et al. Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenovirus vectors and facilitates repeated administration to mouse airway. Gene Ther 4 (1997) 611-617
12. Klonjkowski B., GilardiHebenstreit P., Hadchouel J., et al. A recombinant El-deleted canine adenoviral vector capable of transduction and expression of a transgene in human-derived cells and in vivo. Hum Gene Ther 8 (1997) 2103-2115
13. Snoeck H.W., Tao W.J., and Klotman M.E. Adeno-associated viral vectors: Background and technical aspects. Exp Nephrol 5 (1997) 514-520
14. Feng M., Jackson W.H., Goldman C.K., et al. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat Biotechnol 15 (1997) 866-870
15. Bischoff J.R., Kirn D.H., Williams A., et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274 (1996) 373-376
16. Heise C., Sampson-Johannes A., Williams A., et al. ONYX-015, an Elb gene attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3 (1997) 639-645
17. Duque P.M., Alonso C., Sanchez-Prieto R., et al. Antitumoral effect of EIB defective adenoviruses in human malignant cells. Gene Ther 5 (1998) 286-287
18. Gagnebin J., Kovar H., Kajava A.V., et al. Use of transcription reporters with novel p53 binding sites to target tumour cells expressing endogenous or virally transduced p53 mutants with altered sequence-specificity. Oncogene 16 (1998) 685-690
19. Da Costa L.T., Jen J., He T.C., et al. Converting cancer genes into killer genes. Proc Natl Acad Sci USA 93 (1996) 4192-4196
20. supp. Hallenbeck P.L., Chang Y.-N., Stewart D., et al. Novel tumor specific replication restricted adenoviral vector for gene therapy of liver cancer. Cancer Gene Ther 4 (1997) 038
21. Brown M.A. Tumor suppressor genes and human cancer. Adv Genet 36 (1997) 45-135
22. Meng RD, El-Deiry WS. Tumor suppressor genes as targets for cancer gene therapy. In 'Gene Therapy of Cancer' Lattime EC, Gersou SL, eds, in press.
23. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 88 (1997) 323-331
24. El-Deiry W.S. p21/p53 cellular growth control, and genomic integrity. Curr Top Microbiol Immunol 227 (1998) 121-137
25. Baker S.J., Markowitz S., Fearon E.R., et al. Suppression of human colorectal carcinoma cell growth by wild type p53. Science 249 (1990) 912-915
26. Roth J.A., and Cristiano R.I. Gene therapy for cancer: What have we done and where are we going?. J Natl Cancer Inst 89 (1997) 21-39
27. Nielsen L.L., and Maneval I. p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 5 (1998) 52-63
28. Blagosklonny M.V., and El-Deiry W.S. In vitro evaluation of a p53-expressing adenovirus as an anticancer drug. Int J Cancer 67 (1996) 386-392
29. Blagosklonny M.V., and El-Deiry W.S. Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. Int J Cancer 75 (1998) 933-940
30. Weinstein J.N., Myers T.G., O'Connor P.M., et al. An information-intensive approach to the molecular pharmacology of cancer. Science 275 (1997) 343-349
31. El-Deiry W.S., Tokino T., Velculescu V.E., et al. WAFI, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
32. Harper J.W., Adami G.R., Wei N., et al. The p21 cdk-interacting protein Cipl is a potent inhibitor of Gl cyclin dependent kinases. Cell 75 (1993) 805-816
33. Xiong Y., Hannon G.J., Zhang H., et al. p21 is a universal inhibitor of cyclin kinases. Nature 366 (1993) 701-704
34. Harper J.W., Ellege S.J., Keyomarsi K., et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6 (1995) 387-400
35. Katayose D., Wersto R., Cowun K.H., and Seth P. Effects of a recombinant adenovirus expressing WAFI/CIPI on cell growth, cell cycle and apoptosis. Cell Growth Differ 6 (1995) 1207-1212
36. Yang Z.-Y., Perkins N.D., Ohno T., et al. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat Med 1 (1995) 1052-1056
37. Prabhu N.S., Blagosklonny M.V., Zeng Y.-X., et al. Suppression of cancer cell growth by adenovirus expressing p21 WAFI/CIP I deficient in PCNA interaction. Clin Cancer Res 2 (1996) 1221-1229
38. Meng R.D., Shih H., Prabhu N.S., et al. Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression. Clin Cancer Res 4 (1998) 251-259
39. Katayose Y., Kim M., Rakkar A., et al. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 57 (1997) 5441-5445
40. Chen J., Willingham T., Shuford M., et al. Tumor suppression and inhibition of anceuploid cell accummulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27. Kipl. J Clin Invest 97 (1996) 1983-1988
41. p27(Kipl) induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene 14 (1997) 2283-2289
42. Koff A., Ohtsuki M., Polyak K., et al. Negative regulation of GI in mammalian cells: inhibition of cyclin E dependent kinase by TGF-β. Science 260 (1993) S36-S39
43. Liggett Jr. W.H., and Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16 (1998) 1197-1206
44. INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. Oncogene 16 (1998) 265-272
45. Fueyo J., Gomez-Manzano C., Puduvalli V.K., et al. Adenovirus-mediated p16 transfer to glioma cell induces G(I) arrest and protects from paclitaxel and topotecan: implications for therapy. Int J Oncol 12 (1998) 665-669
46. CDKN4) in human prostate cancers. J Urol 158 (1997) 636-641
47. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 81 (1995) 323-330
48. Sellers W.R., and Kaelin Jr. W.G. Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 15 (1997) 3301-3312
49. Xu H.J. Strategies for approaching retinoblastoma tumor suppressor gene therapy. Adv Pharmacol 40 (1997) 369-397
50. Tait D.L., Obermiller P.S., RedlinFrazier S., et al. A Phase I trial of retroviral BRCAIsv gene therapy in ovarian cancer. Clin Cancer Res 3 (1997) 1959-1968
51. Hargest R., Eldin A., and Williamson R. Gene therapy for familial adenomatous polyposis using the adenomatous polyposis coli gene - prolonged expression of the APC gene after lipofection into mouse colon in vivo. Cancer Gene Ther 4 (1997) 322-323
52. Canman C.E., and Kastan M.B. Role of p53 in apoptosis. Adv Pharmacol 41 (1997) 429-460
53. Fuchs E.J., McKenna K.A., and Bedi A. p53-dependent DNA damage-induced apoptosis requires Fas/Apo-I-independent activation of CPP32ß. Cancer Res 57 (1997) 2550-2554
54. Wu G.S., Burns T.F., McDonald III E.R., et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 17 (1997) 141-143
55. Arai H., Gordon D., Nabel E.G., and Nabel G.J. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci USA 94 (1997) 13862-13867
56. Ealovega M.W., McGinnis P.K., Sumantram V.N., et al. bcl-xs gene therapy induces apoptosis of human mammary tumors in nude mice. Cancer Res 56 (1996) 1965-1969
57. Ouchi T., Monteiro A., August A., et al. BRCAI regulates p53-dependent gene expression. Proc Natl Acad Sci USA 95 (1998) 2302-2306
58. Zhang H.B., Somasundaram K., Peng Y., et al. BRCAI physically associates with p53 and stimulates its transcriptional activity. Oncogene 16 (1998) 1713-1721
59. INGI cooperates with p53 in cell growth control. Nature 391 (1998) 295-298
60. INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat Med 3 (1997) 313-319
61. Mobley S.R., Liu T.J., Hudson J.M., and Clayman G.L. In vitro growth suppression by adenoviral transduction of p21 and p16 in squamous cell carcinoma of the head and neck - a research model for combination gene therapy. Arch Otolaryngol 124 (1998) 88-92
62. Conseiller E., Debussche L., Landais D., et al. CTSI: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties. J Clin Invest 101 (1998) 120-127
63. p57KIP2 requires binding to proliferating cell nuclear antigen. Proc Natl Acad Sci USA 95 (1998) 1392-1397
64. Xu H.J., Zhou Y.L., Seigne J., et al. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res 56 (1996) 2245-2249
65. Roth J.A., Nguyen D., Lawrence D.D., et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2 (1996) 985-991
66. Nguyen D.M., Spitz F.R., Yen N., et al. Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiov Sur 112 (1996) 1372-1376
67. Suppl. Merritt J.A., Clayman G.L., Swisher S., et al. Clinical phase I experience with INGN 201 (Ad-p53) in non-small cell lung and head and neck cancer. Cancer Gene Ther 4 (1997) 01
68. Suppl. Horowitz J.A., Maneval D.C., Rybak M.E., et al. Intra-arterial p53 gene therapy of liver malignancies: preclinical studies and initial clinical observations. Cancer Gene Ther 4 (1997) 03
69. No stranger to controversy. Nat Genet 17 (1997) 247-248
70. Suppl. Kirn D., Ganley I., Nemunaitis J., et al. A phase I clinical trial with ONYX-015 (a selectively replicating adenovirus) administered by intratumoral injection in patients with recurrent head and neck carcinoma. Cancer Gene Ther 4 (1997) 05
71. Suppl. Heise C., Williams A., Propst M., et al. Preclinical studies with ONYX-015 (a replication competent EIB-deleted adenovirus) in combination with chemotherapy. Cancer Gene Ther 4 (1997) 06
72. abstract #1564. Kirn D.H., Heise C., Mangold G., and Von Hoff D. ONYX-015, a selectively replicating adenovirus, has antitumoral activity following IV administration alone and in combination with chemotherapy. Proc Am Soc Clin Oncol (1998)